The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Andrew Tsai - Jefferies - Analyst
: Hey, good afternoon. Thanks for taking my questions and congrats on the quarter.
Maybe two questions on my side. The first one on overall guidance and calibrate. So in terms of the total revenue guidance, just curious what
dynamics are you guys specifically assuming for you to guide to the low end as well as the high end of your total revenue guidance?
And secondly, if we backed out the individual products other than Qelbree from your total revenue guidance for 2024. Is it reasonable to assume
your guidance might imply Qelbree sales could come in above consensus of around $210 million currently Thanks.
Question: Andrew Tsai - Jefferies - Analyst
: Perfect. Thanks. And then maybe a follow-up question is on the SPN-817 epilepsy top line interim data Phase 2 data coming up. Will that be a
distinct press release in May? Or will that be shared in conjunction with your Q1 EPS?
And then secondly, could you give us a flavor of what you plan to share that day? Should we expect efficacy curves, safety, AE breakdowns and
other detailed information. So basically just curious how much detail you're planning to provide. Thank you.
Question: Andrew Tsai - Jefferies - Analyst
: Great. Thanks for the color. Appreciate the updates.
Question: David Amsellem - Piper Sandler Companies - Analyst
: Hey, thanks. So wanted to dig a little deeper on Qelbree. So looking at the prescription trends recently and also in the fourth quarter, it looks a little
softer than what we had been seeing. So I wanted to get some perspective on the different moving parts in both the ped and adult ADHD market
and what might be driving the volume trajectory currently?
And also how that ties into your commentary regarding co-pay assistance. I think, Jack, you had mentioned recently that you were paring back
some of that co-pay assistance. So how should we think about the impact there and what does that mean for the prescription directory for Qelbree
going forward?
And then just another question on the guide. Do you have any risk-adjusted contribution for 830 in there? Just wanted to clarify what you may or
may not have on that product as it relates to the overall top line guidance. Thank you.
Question: David Amsellem - Piper Sandler Companies - Analyst
: That's very helpful. Jack, just one quick follow-up. What do you expect the mix between adults and peds will look like as we move through the
latter part of this year?
Question: David Amsellem - Piper Sandler Companies - Analyst
: Okay. Very helpful. Thank you.
Question: Stacy Ku - TD Cowen - Analyst
: Thanks for taking our questions. We have a few. So first, just on payer access reimbursement. Do you have any remaining overall goals this year
and any guidance around any additional formulary wins? So just wondering if you expect any additional contracting this year for Qelbree?
And related to that, what do you think would be a gross to nets this year? Are you providing any guidance for how it might settle over the year?
Just curious since you're saying that right now, the adult doses there is a touch lower, but might be driving kind of the net pricing as we kind of
drive that adult growth? And that's my questions for now. Thanks.
Question: Stacy Ku - TD Cowen - Analyst
: Go ahead. I can follow up with my third question.
Question: Stacy Ku - TD Cowen - Analyst
: Perfect, you just answered my question. Thank you.
| 
